The EU has approved gene therapy for beta-thalassemia.

          The EU gave approval to the Bluebird Bio company to treat beta-thalassemia with gene therapy, which is a one-time treatment for patients aged 12 years or older. Generally, if patients are unable to find stem cell donors for transplantation, they must undergo blood transfusion treatment every 2–¬3 weeks for the rest of their lives. However, transfusion risks organ damage due to the body getting too much iron.
Page view : 176